Last reviewed · How we verify
Prevnar 13®
At a glance
| Generic name | Prevnar 13® |
|---|---|
| Also known as | Pfizer Inc.'s pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein), Pfizer Inc.'s Pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein), PCV13, Prevenar 13, pneumococcal 13-valent conjugate vaccin |
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PHASE3)
- Clinical Trial of PCV24 in Children Aged 2-17 Years (PHASE1)
- Clinical Trial of PCV24 in Infants Aged 2-23 Months (PHASE1)
- Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine (PHASE3)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years (PHASE1)
- Multicenter Pilot Study Evaluating the Immunogenicity of an Innovative Pneumococcal Vaccination Strategy in Splenectomized Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prevnar 13® CI brief — competitive landscape report
- Prevnar 13® updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI